EDIT (37) ALLO (38) AUTL (25) CCCC (27) ⌘ Pro Terminal →

ProKidney Corp. (Class A) (PROK) — RQD Stock Rating Cockpit

$1.47 -3.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ProKidney Corp. (Class A) (PROK) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $444.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-6.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROK)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

36.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE10% OF RANGE

L: $1$1.47H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PROK

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

12/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PROK

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROK)

✓Walkthrough of PROK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PROK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.63%📐 HORIZONTAL RANGE

2026-10-30O $1.41H $1.47L $1.29C $1.47VOL 1.73M

RES: $1.97SUP: $1.30SMA50: $1.67SMA200: $1.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROK Butterfly Map → + Track PROK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PROK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PROK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROK)

Health Care Rank #508 of 1016 ⚔️ EDIT vs PROK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROK vs. EDIT, ALLO, AUTL, CCCC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ProKidney Corp. (Class A) (PROK) ranks #508 by composite RQD confidence (44/100, grade D) and #468 by equity capitalization ($444.4M). Within this direct 5-issuer industry benchmark cohort, PROK leads on earnings valuation at N/A trailing P/E, while PROK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PROK ACTIVE ProKidney Corp. (Class A)	D	44/100	—	—	-35.0%	-3.29%	$444.4M	Benchmark Subject
EDIT Editas Medicine Inc.	D-	37/100	—	—	-35.0%	-0.68%	$450.0M	/edit-vs-prok →
ALLO Allogene Therapeutics Inc.	D-	38/100	—	—	-35.0%	-3.85%	$431.9M	/allo-vs-prok →
AUTL Autolus Therapeutics plc	E	25/100	—	-27.8%	-35.0%	-3.07%	$420.5M	/autl-vs-prok →
CCCC C4 Therapeutics Inc.	E	27/100	—	—	-35.0%	-2.80%	$406.0M	/cccc-vs-prok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850270

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProKidney Corp. (Class A) (PROK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.0M, operating cash flow of -$120.1M, and free cash flow of -$135.3M (+13.2% YoY). On the balance sheet, PROK closed FY2025 with $335.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$69.0M	-$120.1M	-$135.3M	$335.6M	—
FY2024 (FY)	2024-12-31	$0	-$61.2M	-$126.4M	-$155.9M	$441.1M	—
FY2023 (FY)	2023-12-31	$0	-$35.5M	-$90.1M	-$90.1M	—	—

3. PROK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ProKidney Corp. (Class A) (NASDAQ: PROK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.47 (-3.29% 1D, market cap $444.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PROK ranks #508 in composite RQD confidence.

How does PROK compare to EDIT and ALLO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PROK carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M) and ALLO (Allogene Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, PROK leads on earnings multiple (N/A) while PROK leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PROK?

Per PROK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850270), ProKidney Corp. (Class A) generated $0 in revenue, -$69.0M in net income, and -$135.3M in free cash flow against $335.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PROK trading relative to its 50-day, 200-day, and 52-week technical levels?

PROK last traded at $1.47 (-3.29% on volume of 821,235 shares), positioning the stock -11.98% below its 50-day simple moving average ($1.67) and -19.23% below its 200-day simple moving average ($1.82). Across its 52-week range of $1.29 to $3.10, PROK sits at the 9.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).

PROK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PROK stock right now?

ProKidney Corp. (Class A) (PROK) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PROK's 12-month price target and RQD AI Jury consensus?

PROK's 12-month base price target is $1.38 (range $1.08 to $3.26), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PROK RQD Cockpit PROK 12M Forecast PROK Earnings & Move PROK Dividends & DRIP PROK Insiders & 13F PROK Whale Options PROK Profit Sankey PROK News & Why